FDA Approves Reblozyl to Treat Anemia in Some Patients With MDS

The FDA approved luspatercept-aamt (Reblozyl, Celgene) for the treatment of anemia in adults with very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts or a myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis that failed an erythropoiesis-stimulating agent (ESA) and required two or more red blood cell (RBC) units over eight weeks.